@misc{misc480cd69d,
title   = {Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1},
author = {Hurvitz, Sara A. and Andre, Fabrice and Jiang, Zefei and Shao, Zhimin and Neciosup, Silvia P. and Mano, Max S. and Tseng, Ling-Min and Zhang, Qingyuan and Shen, Kunwei and Liu, Donggeng and Dreosti, Lydia M. and Feng, Jifeng and Burris, Howard A. and Toi, Masakazu and Buyse, Marc E. and Cabaribere, David and Lindsay, Mary-Ann and Kunz, Tiffany and Rao, Shantha and Pacaud, Lida B. and Taran, Tetiana and Slamon, Dennis},
year = {2015},
doi = {10.1158/1538-7445.SABCS14-S6-01},
booktitle   = {Annual CTRC-AACR San Antonio Breast Cancer Symposium}
}